Search

Displaying results 2731 - 2740 of 10000 in total
  1. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents. … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  2. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019. … [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872]

  3. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … L44161] Treatment of hemophilia B primarily involves the routine replacement of factor IX using recombinant or donor-derived factor IX products that, while effective, may be burdensome for the patient due

  4. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    Due to its very low water solubility, butamben is considered to be suitable only for topical anesthesia. … Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate.

  5. Drug

    Nitrous oxide

    go.drugbank.com/drugs/DB06690
    ApprovedInvestigationalVet approved

    It is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug. … It is used in surgery and dentistry for its anesthetic and analgesic effects.

    Mixtures: Nitrous Oxide In Oxygen, OXICALM® MEZCLA MEDICINAL DE OXIGENO: OXIDO NITROSOProducts: N/A, Nitrous Oxide 100%
  6. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    [A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved … on August 8, 2024.

    Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)
  7. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

  8. Drug

    MD-0727

    go.drugbank.com/drugs/DB05948
    Investigational

    MD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.

  9. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].

    Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateCategories: Receptors, Prostaglandin E, EP2 Subtype, agonists
  10. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … and cardiovascular disease due to their vasoconstrictive properties.